You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 127 No. 3, March 2009 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Clinical Sciences
 •Online Features
 This Article
 •Full text
 •PDF
 •eFigures
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (3)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Choroidal Neovascularization
 •Retinal/ Chorioretinal Disorders
 •Articles for Residents
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Early Effects of Intravitreal Triamcinolone Acetonide on Inflammation and Proliferation in Human Choroidal Neovascularization

Olcay Tatar, MD; Annemarie Adam, MTA; Kei Shinoda, MD, PhD; Edwin Kaiserling, MD; Vicky Boeyden, MD; Carl Claes, MD; Claus Eckardt, MD; Tillmann Eckert, MD; Grazia Pertile, MD; Gabor B. Scharioth, MD; Efdal Yoeruek, MD; Peter Szurman, MD; Karl Ulrich Bartz-Schmidt, MD; Salvatore Grisanti, MD

Arch Ophthalmol. 2009;127(3):275-281.

Objective  To evaluate the early effects of triamcinolone acetonide (TA) on inflammation, proliferation, and vascular endothelial growth factor (VEGF) in human choroidal neovascularization (CNV).

Methods  Retrospective review of an interventional case series of 29 patients who underwent macular translocation. Fourteen CNV membranes without previous therapy (control CNV group) and 4 CNV membranes excised 3 days after photodynamic therapy (PDT CNV group) comprised the control groups. Eleven patients were treated with intravitreal TA (TA CNV group; n = 5) or PDT and TA combined (PDT+TA CNV group; n = 6) 3 to 9 days preoperatively. The CNV membranes were stained for cytokeratin 18, CD34, VEGF, intercellular adhesion molecule-1 (ICAM-1), E-selectin, CD68, CD45, Ki-67, and Thy-1.

Results  Treatment with TA and PDT+TA resulted in increased immunostaining of ICAM-1 in endothelial cells and the stroma and a higher percentage of Thy-1 expression than controls. The density of macrophages was significantly increased in PDT+TA CNV membranes. Leukocyte density and proliferative activity were lower in TA and PDT+TA CNV membranes. The total VEGF score was significantly increased in TA and PDT+TA CNV membranes compared with the control CNV membranes. Evidence of VEGF in the retinal pigment epithelium of PDT+TA CNV membranes was stronger than in control CNV membranes.

Conclusions  Triamcinolone acetonide has no inhibitory effect on macrophage infiltration or ICAM-1, Thy-1, or VEGF expression in CNV membranes in the early term. The clinical benefits of TA are probably not based on pure antiinflammatory or VEGF-suppressing mechanisms.


Author Affiliations: University Eye Hospital at the Centre for Ophthalmology of the Eberhard-Karls University, Tuebingen, Germany (Drs Tatar, Yoeruek, Szurman, and Bartz-Schmidt); Department of Pathology, University of Tuebingen, Tuebingen, Germany (Dr Kaiserling and Ms Adam); Laboratory of Visual Physiology, National Institute of Sensory Organs, Tokyo, Japan (Dr Shinoda); AZ-Sint Augustinus, Antwerp, Belgium (Drs Boeyden and Claes); Augenklinik der Staedtischen Kliniken, Frankfurt am Main, Germany (Drs Eckert and Eckardt); Department of Ophthalmology, Sacro Cuore Hospital, Negrar, Italy (Dr Pertile); Augenzentrum Recklinghausen, Recklinghausen, Germany (Dr Scharioth); and Department of Ophthalmology, University Eye Hospital Luebeck, Luebeck, Germany (Dr Grisanti).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.